1. Search Result
Search Result
Results for "

nucleoside transport

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108322

    Others Cardiovascular Disease
    NBTGR (p-Nitrobenzylthioguanosine) is a potent inhibitor of nucleoside transport; inhibits adenosine uptake with a Ki of 70 nM.
    NBTGR
  • HY-115366

    Nucleoside Transporters Neurological Disease
    Soluflazine is a nucleoside transport inhibitor with anticonvulsant action. Soluflazine can be used as an antiepileptic agent .
    Soluflazine
  • HY-100957

    Nucleoside Transporters Cardiovascular Disease
    Dilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides .
    Dilazep dihydrochloride
  • HY-W077242

    DNA/RNA Synthesis Cancer
    1,4-Anthraquinone is a potent anticancer agent. 1,4-Anthraquinone blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of cancer cells. 1,4-Anthraquinone can be used to research anti-leukemia .
    1,4-Anthraquinone
  • HY-116042

    Adenosine Receptor Cardiovascular Disease
    FSCPX is a potent and selective irreversible antagonist of A1 adenosine receptor (A1AR), with low nanomolar potency for binding to the A1AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial adenosine level in the guinea pig atrium .
    FSCPX
  • HY-123360

    BIBW22BS

    Others Cancer
    BIBW 22 (BIBW22BS) is a dipyridamole analogue. BIBW 22 is a potent bifunctional modulator that affects p-glycoprotein and nucleoside transport in tumor cells .
    BIBW 22
  • HY-106841A

    (-)-Draflazine; (S)-R-75231; (S)-R88021

    Adenosine Receptor Drug Isomer Others
    (S)-Draflazine ((-)-Draflazine) is the (S)-configuration of Draflazine (HY-106841). (S)-Draflazine is a potent blocker of nucleoside transport .
    (S)-Draflazine
  • HY-U00049

    Calcium Channel Cardiovascular Disease Neurological Disease
    Mioflazine is an orally active nucleoside transport inhibitor with sleep-improving activity. Mioflazine significantly improves cardiac survival after global cardiac ischemia. Mioflazine inhibits nucleoside uptake Mioflazine does not exhibit inotropic effects during induction and nursing .
    Mioflazine
  • HY-U00049B

    Calcium Channel Cardiovascular Disease Neurological Disease
    Mioflazine dihydrochloride is a nucleoside transport inhibitor with sleep-improving activity. Mioflazine dihydrochloride significantly improves cardiac survival after global cardiac ischemia. Mioflazine dihydrochloride reduces the mitochondrial calcium content in guinea-pig. Mioflazine dihydrochloride does not exhibit inotropic effects during induction and nursing .
    Mioflazine di(hydrochloride)
  • HY-U00049A

    Calcium Channel Cardiovascular Disease Neurological Disease
    Mioflazine dihydrochloride hydrate is a nucleoside transport inhibitor with sleep-improving activity. Mioflazine dihydrochloride hydrate helps maintain the mechanical function of the left ventricle and significantly improves the heart's recovery ability after global ischemia at new temperatures. Mioflazine dihydrochloride hydrate reduces the mitochondrial calcium content in guinea-pig .
    Mioflazine (di(hydrochloride) hydrate)
  • HY-N7119

    Others Inflammation/Immunology
    Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity . Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function .
    Cimicifugoside